Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4100562 | 0.90 | KMT2A (0.55) | SMN1; SMN2RAB9ANPC1MAPK14MMP1 | |
| SCHEMBL4092508 | 0.79 | MMP1 (0.49) | SMN1; SMN2RAB9ANPC1MMP1KMT2A | |
| SCHEMBL4086212 | 0.76 | HSD17B1 (0.60) | SMN1; SMN2RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL9090227 | 0.75 | SMN1; SMN2 (0.61) | SMN1; SMN2RAB9AKMT2AMEN1POLB | |
| Hydrochloric Acid SCHEMBL9677581 | 0.74 | SMN1; SMN2 (0.59) | SMN1; SMN2RAB9AKMT2AMEN1POLB | |
| SCHEMBL4085481 | 0.74 | MAPT (0.47) | SMN1; SMN2RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL9779435 | 0.73 | KMT2A (0.60) | SMN1; SMN2RAB9AKMT2AMEN1POLB | |
| SCHEMBL6665224 | 0.72 | HPGD (0.68) | SMN1; SMN2RAB9AKMT2AMEN1POLB | |
| SCHEMBL4085277 | 0.72 | HSD17B1 (0.60) | SMN1; SMN2MAPK14MMP1KMT2APOLB | |
| SCHEMBL18381293 | 0.71 | KMT2A (0.55) | SMN1; SMN2RAB9ANPC1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186900-A1 | COMPOUND | STERIX LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| US-20090186900-A1 | COMPOUND | STERIX LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| US-20090186900-A1 | COMPOUND | STERIX LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| WO-2007096647-A2 | DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER | STERIX LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186900-A1 | COMPOUND | HSD17B2, HSD17B11, CYP17A1 | SMN1; SMN2 1091/4885RAB9A 3860/4885NPC1 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.